Revvity Inc (RVTY)

Currency in USD
117.75
+1.22(+1.05%)
Closed·
117.750.00(0.00%)
·
Earnings results expected in 6 days
RVTY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
116.57118.30
52 wk Range
81.36128.29
Key Statistics
Prev. Close
117.75
Open
116.85
Day's Range
116.57-118.3
52 wk Range
81.36-128.29
Volume
1.88M
Average Volume (3m)
1.47M
1-Year Change
-4.2916%
Book Value / Share
63.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RVTY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
116.19
Downside
-1.33%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Revvity Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Revvity Inc Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Revvity Inc Earnings Call Summary for Q3/2025

  • Revvity reported Q3 2025 adjusted EPS of $1.18 (beating $1.14 forecast) while revenue of $699M fell slightly short of expectations, leading to a 2.47% stock decline
  • The company maintained a 26.1% adjusted operating margin with 1% organic growth, as diagnostics grew 2% while life sciences remained flat
  • Geographic performance showed growth in Americas and Europe but decline in Asia due to China's changing diagnostics reimbursement policies
  • CEO Prahlad Singh expressed optimism about easing market uncertainties while highlighting AI initiatives as key growth drivers
  • Full-year guidance set at $2.83-2.88B revenue and $4.90-5.00 adjusted EPS, with projected 2-3% organic growth for 2026 and 28% baseline operating margin
Last Updated: 2025-10-30, 12:40 p/m
Read Full Transcript

Compare RVTY to Peers and Sector

Metrics to compare
RVTY
Peers
Sector
Relationship
P/E Ratio
57.4x29.8x−0.6x
PEG Ratio
−16.981.490.00
Price/Book
1.8x3.1x2.6x
Price / LTM Sales
4.7x3.0x3.4x
Upside (Analyst Target)
−1.3%−2.7%40.5%
Fair Value Upside
Unlock9.1%4.4%Unlock

Analyst Ratings

11 Buy
8 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 116.19
(-1.33% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Buy115.00-2.34%-MaintainDec 19, 2025
Wells Fargo
Hold107.00-9.13%102.00MaintainDec 15, 2025
BofA Securities
Hold110.00-6.58%105.00DowngradeDec 15, 2025
Barclays
Buy115.00-2.34%105.00MaintainDec 15, 2025
Goldman Sachs
Hold105.00-10.83%-New CoverageDec 09, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.95%
Dividend Yield
0.24%
Industry Median 1.42%
Annualized payout
0.28
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Oct 27, 2025
EPS / Forecast
1.18 / 1.14
Revenue / Forecast
699.00M / 699.39M
EPS Revisions
Last 90 days

RVTY Income Statement

People Also Watch

129.95
HIG
+0.30%
153.12
NTRS
+6.02%
177.90
CHRW
-0.83%
160.80
EXPD
-1.05%
273.94
NDSN
+0.31%

FAQ

What Is the Revvity (RVTY) Stock Price Today?

The Revvity stock price today is 117.75

What Stock Exchange Does Revvity Trade On?

Revvity is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Revvity?

The stock symbol for Revvity is "RVTY."

Does Revvity Pay Dividends? What’s The Current Dividend Yield?

The Revvity dividend yield is 0.24%.

What Is the Revvity Market Cap?

As of today, Revvity market cap is 13.35B.

What Is Revvity's Earnings Per Share (TTM)?

The Revvity EPS (TTM) is 1.95.

When Is the Next Revvity Earnings Date?

Revvity will release its next earnings report on Jan 29, 2026.

From a Technical Analysis Perspective, Is RVTY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Revvity Stock Split?

Revvity has split 4 times.

How Many Employees Does Revvity Have?

Revvity has 11000 employees.

What is the current trading status of Revvity (RVTY)?

As of Jan 23, 2026, Revvity (RVTY) is trading at a price of 117.75, with a previous close of 117.75. The stock has fluctuated within a day range of 116.57 to 118.30, while its 52-week range spans from 81.36 to 128.29.

What Is Revvity (RVTY) Price Target According to Analysts?

The average 12-month price target for Revvity is USD116.19, with a high estimate of USD140 and a low estimate of USD100. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -1.33% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.